<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1643">
  <stage>Registered</stage>
  <submitdate>7/08/2007</submitdate>
  <approvaldate>7/08/2007</approvaldate>
  <nctid>NCT00513422</nctid>
  <trial_identification>
    <studytitle>The Long-term Evaluation of Glucosamine Sulphate Study</studytitle>
    <scientifictitle>The Effect of Glucosamine Sulphate on Structural Disease Progression in Knee Osteoarthritis and the Cost-effectiveness of Glucosamine Sulphate for Knee Arthritis.</scientifictitle>
    <utrn />
    <trialacronym>LEGS</trialacronym>
    <secondaryid>NHMRC 402511</secondaryid>
    <secondaryid>GI-IM-LEGS-L</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis, Knee</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Glucosamine sulphate and chondroitin
Other interventions - Glucosamine sulphate
Other interventions - Chondroitin sulphate
Other interventions - Placebo capsules for glucosamine and chondroitin

Experimental: 1 - Glucosamine sulfate 1500mg and chondroitin sulfate 800mg (low molecular weight, bovine)

Experimental: 2 - Glucosamine sulfate 1500mg

Experimental: 3 - Chondroitin sulfate 800mg

Placebo Comparator: 4 - Matching glucosamine/chondroitin placebo capsules


Other interventions: Glucosamine sulphate and chondroitin
Glucosamine: Two 750mg capsules once daily for two years;
Chondroitin: Two 400mg capsules once daily for two years.

Other interventions: Glucosamine sulphate
Glucosamine: Two 750mg capsules once daily for two years;
Placebo Chondroitin: Two capsules once daily for two years.

Other interventions: Chondroitin sulphate
Chondroitin sulphate: Two 400mg capsules once daily for two years;
Placebo glucosamine: Two capsules once daily for two years.

Other interventions: Placebo capsules for glucosamine and chondroitin
Two placebo glucosamine capsules once daily for two years;
Two placebo chondroitin capsules once daily for two years.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Medial tibio-femoral joint space narrowing (mm)</outcome>
      <timepoint>MRI (1 year) Radiographs (2 years)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Knee pain (11 point Likert scale)</outcome>
      <timepoint>Bimonthly for 1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>WOMAC</outcome>
      <timepoint>1 year, 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patients global assessment</outcome>
      <timepoint>Bimonthly for 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total NSAIDs use</outcome>
      <timepoint>Bimonthly for 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>General health status (SF-12v2)</outcome>
      <timepoint>1 year, 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cost-effectiveness (cost per OMERACT-OARSI responder)</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Leisure time physical activity</outcome>
      <timepoint>1 year, 2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Knee pain, or taking NSAIDs/ analgesia for knee pain on most days past month

          -  Knee pain 4-10 on 10cm VAS

          -  Medial tibio-femoral compartment joint space narrowing in symptomatic knee</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Unstable diabetes

          -  &lt;2mm medial tibio-femoral compartment joint space width</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2011</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Marlene Fransen - Sydney</hospital>
    <postcode>1825 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary aim of this study is to determine if the dietary supplements, glucosamine
      sulphate and/or chondroitin can limit or reduce structural disease progression whilst
      providing symptomatic benefit in people with osteoarthritis (OA) of the knee.

      The specific hypotheses to be tested in the proposed double blind, placebo-controlled,
      randomised clinical trial are that, compared to participants allocated to placebo,
      participants allocated to either or both of these dietary supplements will demonstrate:

        -  reduced medial tibio-femoral joint space narrowing at 2 years AND;

        -  reduced knee pain over 1 year

      These benefits will be achieved by participants allocated to glucosamine sulphate and/or
      chondroitin (the study treatments) without concomitant:

        -  increased use of analgesics

        -  reduced health-related quality of life

        -  reduced participation in leisure-time physical activity</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00513422</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Marlene Fransen, PhD, MPH</name>
      <address>University of Sydney, Faculty of Health Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>